Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review

Figure 1 Hepatocellular carcinoma in segment VIII at diagnosis. A: Contrast-enhanced computed tomography (CT) arterial phase; B: Contrast-enhanced CT venous phase; C: Magnetic resonance imaging with liver-specific contrast agent.

Figure 2 Treatment plan (prescription dose 3 × 12. 5 Gy to 65% surrounding isodose). A: Isodose plan in axial view; B: Frontal view; C: Sagittal view, broad red line: Planning target volume (PTV), yellow line: PTV-surrounding 65% isodose = 37.5 Gy, light blue line: Internal target volume (ITV), narrow red line: ITV-surrounding 80% isodose = 46.2 Gy, dark blue line: 40% isodose = 23.1 Gy.

Figure 3 Complete response 9 months after transarterial chemoembolization and stereotactic body radiation therapy. A: Contrast-enhanced computed tomography (CT) arterial phase; B: Contrast-enhanced CT venous phase; C: Magnetic resonance imaging with liver-specific contrast agent.